Mercaptopurine (6-MP)

Catalog No.S1305

Mercaptopurine (6-MP) Chemical Structure

Molecular Weight(MW): 152.18

Mercaptopurine is a widely used antileukemic agent and immunosuppressive drug that inhibits de novo purine synthesis through incorporation of thiopurine methyltransferase metabolites into DNA and RNA.

Size Price Stock Quantity  
In DMSO USD 100 In stock
USD 97 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Mercaptopurine is a widely used antileukemic agent and immunosuppressive drug that inhibits de novo purine synthesis through incorporation of thiopurine methyltransferase metabolites into DNA and RNA.
Targets
PRPP Amidotransferase [2]
In vitro

Mercaptopurine is widely used to treat malignancies, rheumatic diseases, dermatologic conditions, inflammatory bowel disease, and solid organ transplant rejection. [1] Mercaptopurine inhibits purine nucleotide synthesis and metabolism by inhibiting an enzyme called Phosphoribosyl pyrophosphate amidotransferase (PRPP Amidotransferase). PRPP Amidotransferase is the rate limiting enzyme of purine synthesis. It alters the synthesis and function of RNA and DNA . Mercaptopurine interferes with nucleotide interconversion and glycoprotein synthesis. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
L1210 leukemia cells NFOwNlhHfW6ldHnvckBie3OjeR?= MorITY5pcWKrdH;yfUBkd26lZX70doF1cW:wIH;uJI12dHSrZIL1[{1z\XOrc4ThcpQhVDF{MUCgcIV2c2WvaXGgZ4VtdHNuIFnDOVA:OC5yMkSg{txO NG\XVZIyQTB4MUC3
MT4 cells MVPQdo9tcW[ncnH0bY9vKGG|c3H5 M{fWSWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTWS0JINmdGy|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlEh|ryP MYKxO|I2PDZ4OR?=
human CCRF-CEM cells NFPlOmNRem:uaX\ldoF1cW:wIHHzd4F6 M3v5[2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQ1PSSk1ETU1iY3XscJMh[nliTWTUJIF{e2G7LDDJR|UxRTFizszN Ml;JNVczPTR4Nkm=
human CCRF-SB cells NFvsfG9Rem:uaX\ldoF1cW:wIHHzd4F6 MoL2RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCFQ2LGMXNDKGOnbHzzJIJ6KE2WVDDhd5NigSxiSVO1NF0yKM7:TR?= Mly0NVczPTR4Nkm=
human SK-MEL-28 cells NV7uc|RMWHKxbHnm[ZJifGmxbjDhd5NigQ>? NWfBfJhYSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTT{1OTUxvMkigZ4VtdHNiYomgUXRVKGG|c3H5MEBKSzVyPUG1JO69VQ>? M1zkUFE4OjV2Nk[5
human MCF7 cells NXz0Tml6WHKxbHnm[ZJifGmxbjDhd5NigQ>? NIrQSVdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlch[2WubIOgZpkhVVSWIHHzd4F6NCCLQ{WwQVMh|ryP MVuxO|I2PDZ4OR?=
human HepG2 cells NUWyN29vWHKxbHnm[ZJifGmxbjDhd5NigQ>? MUHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEincFeyJINmdGy|IHL5JG1VXCCjc4PhfUwhUUN3ME24JO69VQ>? NHi4dHcyPzJ3NE[2PS=>
human DU145 cells NUTMfo5DWHKxbHnm[ZJifGmxbjDhd5NigQ>? Mn;URY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCGVUG0OUBk\WyuczDifUBOXFRiYYPzZZktKEmFNUC9NkDPxE1? NV[2b2tROTd{NUS2Olk>
mouse J774.A1 cells M{G2NnBzd2yrZnXyZZRqd25iYYPzZZk> Ml7uN{Bl[Xm| NFHi[lFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFq3O|QvSTFiY3XscJMh[W[2ZYKgN{Bl[Xm|IHL5JG1VXCClb372[ZJ{cW:wIHHzd4F6NCCLQ{WwQVAvODB|IN88US=> NHPHOYQyPjZ2M{C0NC=>
HEK293 cells MnPYVJJwdGmoZYLheIlwdiCjc4PhfS=> MUCzJIRigXN? MlXGRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDISWszQTNiY3XscJMh[W[2ZYKgN{Bl[Xm|IHL5JG1VXCClb372[ZJ{cW:wIHHzd4F6NCCLQ{WwQVAvODB5IN88US=> MUixOlY1OzB2MB?=
mouse J774 cells MV7Qdo9tcW[ncnH0bY9vKGG|c3H5 M3ntWFczKGh? NHLmTmRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFq3O|Qh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKG:oIHPlcIwh\3Kxd4ToJIFnfGW{IEeyJIhzeyCkeTDNWHQhdWW2aH;kMEBKSzVyPUCuNFA{KM7:TR?= M1i1cVExPzV5N{C4
human PBMC MlLySpVv[3Srb36gZZN{[Xl? NXjsZZlOPCCmYYnz MknqTY5pcWKrdHnvckBw\iCWIHPlcIwhdWm2b3flck1qdmS3Y3XkJIJt[XO2b3flcoV{cXNiaX6gbJVu[W5iUFLNR{Bi\nSncjC0JIRigXNuIFnDOVA:OC5zNEm1JO69VQ>? MnPuNVg1PjdyMEe=
HeLa cells NVTneZNOS3m2b4TvfIlkcXS7IHHzd4F6 MYG0PEBp MVPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[WxiKGOnbHzzJIF1KGyjZzDwbIF{\SCxZjDndo94fGhiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0zNjlizszN NV6zPWd6OTl5MUG5PFc>
A549 cells M1X2UWN6fG:2b4jpZ4l1gSCjc4PhfS=> NHTqR3A1QCCq NUX2SppCS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjdDDsZYcheGijc3Wgc4Yh\3Kxd4ToJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;NEeg{txO MWOxPVcyOTl6Nx?=
MCF7 cells NHvER41EgXSxdH;4bYNqfHliYYPzZZk> NV;jbVd2PDhiaB?= NXfQVJpRS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCjdDDsZYcheGijc3Wgc4Yh\3Kxd4ToJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MT60JO69VQ>? M{PJXVE6PzFzOUi3
MT4 cells M2m1O2N6fG:2b4jpZ4l1gSCjc4PhfS=> MXG5OkBp MlP1R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUXQ1KGOnbHzzJIlv\mWldHXkJJdqfGhiSGTMWk0yKGGodHXyJFk3KGi{czDifUBOXFRiYYPzZZktKEOFNUC9NE4yKM7:TR?= NUSxOFlrOjF5NEGxN|A>
CCRF-CEM cells MYTQdo9tcW[ncnH0bY9vKGG|c3H5 NWHISpdoQTZiaB?= MWTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEOFUl[tR2VOKGOnbHzzJIFnfGW{IEm2JIhzeyCkeTDNWHQh[XO|YYmsJGNEPTB;MTFOwG0> M4T6OFIyPzRzMUOw
WIL2-NS cells NHrRTFdRem:uaX\ldoF1cW:wIHHzd4F6 MkPoPVYhcA>? NWHvZYEySW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDXTWwzNU6VIHPlcIx{KGGodHXyJFk3KGi{czDifUBOXFRiYYPzZZktKEOFNUC9N{DPxE1? M1W0T|IyPzRzMUOw
CCRF-SB cells MmfQVJJwdGmoZYLheIlwdiCjc4PhfS=> MWi5OkBp MV\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEOFUl[tV2Ih[2WubIOgZYZ1\XJiOU[gbJJ{KGK7IF3UWEBie3OjeTygR2M2OD1zLkGg{txO MVGyNVc1OTF|MB?=
human DU145 cells MVvQdo9tcW[ncnH0bY9vKGG|c3H5 NV76eFVNQTZiaB?= MWPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKESXMUS1JINmdGy|IHHmeIVzKDl4IHjyd{BjgSCPVGSgZZN{[XluIFPDOVA:OiEQvF2= NWq3dY5FOjF5NEGxN|A>
human HepG2 cells MYLQdo9tcW[ncnH0bY9vKGG|c3H5 MmPWPVYhcA>? NUW1O4QySW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{Bi\nSncjC5OkBpenNiYomgUXRVKGG|c3H5MEBESzVyPUig{txO NWG5dm95OjF5NEGxN|A>
MCF7 cells M4TlRnBzd2yrZnXyZZRqd25iYYPzZZk> Mk[xPVYhcA>? MXzBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkegZ4VtdHNiYX\0[ZIhQTZiaILzJIJ6KE2WVDDhd5NigSxiQ1O1NF0{NjJizszN M3HwRVIyPzRzMUOw
SK-MEL-28 cells NGT2WndRem:uaX\ldoF1cW:wIHHzd4F6 NHnUNGM6PiCq MlP2RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCVSz3NSWwuOjhiY3XscJMh[W[2ZYKgPVYhcHK|IHL5JG1VXCCjc4PhfUwhS0N3ME2xOUDPxE1? MXqyNVc1OTF|MB?=
MCF7 cells NV7JZXl5S3m2b4TvfIlkcXS7IHHzd4F6 MWLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzMEBKSzVyPUKuO|kh|ryP NWDpe3d5OjN2MUG5NVU>
mouse S49 cells M4rBbWN6fG:2b4jpZ4l1gSCjc4PhfS=> M4rNOVczKGh? Mnr0R5l1d3SxeHnjbZR6KGGpYXnud5Qhf2muZDD0fZBmKG2xdYPlJHM1QSClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA4OiCqcoOgZpkhfHK7cHHuJIJtfWViZYjjcJV{cW:wIHHzd4F6NCCHQ{WwQVgh|ryP M363ZVIzOTZ3OB?=
Colo-357 cells NHrBT4lEgXSxdH;4bYNqfHliYYPzZZk> NXrRXY5VS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hS2:ubz2zOVch[2WubIOgZpkh[3K7c4ThcEB3cW:uZYSgd5RicW6rbnesJGlEPTB;Nj6xNkDPxE1? NHnRNoozODl|MEGyNy=>
Aspc-1 cells Mn\CR5l1d3SxeHnjbZR6KGG|c3H5 NWrvcplyS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSXOyYz2xJINmdGy|IHL5JINzgXO2YXygeolwdGW2IIP0ZYlvcW6pLDDJR|UxRTJwNEWg{txO NWTzUFd2OjB7M{CxNlM>
A549 cells MlzVR5l1d3SxeHnjbZR6KGG|c3H5 NVvJXGRMPDhiaB?= M1v0fmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMh[XO|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME20O{DPxE1? MWqyNlcxPTByMR?=
MCF7 cells MV7DfZRwfG:6aXPpeJkh[XO|YYm= MVy0PEBp MX;DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIF{e2W|c3XkJIF{KGOnbHygeoli[mmuaYT5JIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MT60JO69VQ>? NY\mTJRFOjJ5MEWwNFE>
Patu-02 cells NVzzWWdMS3m2b4TvfIlkcXS7IHHzd4F6 NF3POnJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBR[XS3LUCyJINmdGy|IHL5JINzgXO2YXygeolwdGW2IIP0ZYlvcW6pLDDJR|UxRTlwNkmg{txO NXH4UoRSOjB7M{CxNlM>
Patu-T cells NGDteXdEgXSxdH;4bYNqfHliYYPzZZk> MXHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQZZR2NVRiY3XscJMh[nliY4L5d5RidCC4aX;s[ZQhe3SjaX7pcoctKEmFNUC9OE4xQSEQvF2= NVzNOGZEOjB7M{CxNlM>
Patu-S cells MXrDfZRwfG:6aXPpeJkh[XO|YYm= NGHCTpVEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBR[XS3LWOgZ4VtdHNiYomgZ5J6e3SjbDD2bY9t\XRic4ThbY5qdmduIFnDOVA:OTFwMEeg{txO NUe5foJMOjB7M{CxNlM>
T3M4 cells MV7DfZRwfG:6aXPpeJkh[XO|YYm= NF3lXXNEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBVO012IHPlcIx{KGK7IHPyfZN1[WxidnnvcIV1KHO2YXnubY5oNCCLQ{WwQVIvPjNizszN NHzGVm0zODl|MEGyNy=>
human PANC1 cells NF\3b3dEgXSxdH;4bYNqfHliYYPzZZk> NX\LdYVWS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWEGQQ{GgZ4VtdHNiYomgZ5J6e3SjbDD2bY9t\XRic4ThbY5qdmduIFnDOVA:Pi5|OTFOwG0> Mo\sNlA6OzBzMkO=
human DAN-G cells MnzvR5l1d3SxeHnjbZR6KGG|c3H5 Ml3hR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gSGFPNUdiY3XscJMh[nliY4L5d5RidCC4aX;s[ZQhe3SjaX7pcoctKEmFNUC9OE4xPiEQvF2= Mkn4NlA6OzBzMkO=
HeLa cells NYjUbVc3S3m2b4TvfIlkcXS7IHHzd4F6 M4XYeVQ5KGh? Mlu3R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVN[SClZXzsd{Bie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUKuPUDPxE1? MoTGNlI4ODVyMEG=
WEHI164 cells Mo\QVJJwdGmoZYLheIlwdiCjc4PhfS=> MWmzJIRigXN? NUXsZ2l5SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBud3W|ZTDXSWhKOTZ2IHPlcIx{KGGodHXyJFMh\GG7czDifUBOXFRiY3;ueoVze2mxbjDhd5NigSxiSVO1NF0xNjBzNTFOwG0> M{XPOVE3PjR|MESw
WIL-2NS cells NUDPc4hJWHKxbHnm[ZJifGmxbjDhd5NigQ>? MVPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFeLTD2yUnMh[2WubIOgZpkhVVSWIHHzd4F6NCCLQ{WwQVMh|ryP Mm\JNVczPTR4Nkm=
WEHI164 cells M4fF[nBzd2yrZnXyZZRqd25iYYPzZZk> NULTeol3PzJiaB?= M2HvdWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViV1XITVE3PCClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25ib3[gZ4VtdCCpcn;3eIgh[W[2ZYKgO|IhcHK|IHL5JG1VXCCvZYToc4QtKEmFNUC9NE4xOTdizszN MYGxNFc2PzdyOB?=

... Click to View More Cell Line Experimental Data

Protocol

Solubility (25°C)

In vitro DMSO 30 mg/mL (197.13 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 152.18
Formula

C5H4N4S

CAS No. 50-44-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00514982 Withdrawn Hermanski-Pudlak Syndrome|Colitis|Cytokines|Lymphocytes|Drug Evaluation National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) August 7, 2007 Phase 2
NCT03007147 Not yet recruiting B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|BCR-ABL1 Fusion Protein Expression|Minimal Residual Disease|Philadelphia Chromosome Positive|T Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia Childrens Oncology Group|National Cancer Institute (NCI) July 2017 Phase 3
NCT02578511 Not yet recruiting Acute Lymphoblastic Leukemia in Complete Remission|Lymphoblastic Lymphoma in Complete Remission|Mixed Phenotype Acute Leukemia in Complete Remission Ehab L Atallah|Medical College of Wisconsin January 2017 Phase 1
NCT03020030 Not yet recruiting Acute Lymphoblastic Leukemia, Pediatric Dana-Farber Cancer Institute|Baxalta US Inc. January 2017 Phase 3
NCT02828358 Not yet recruiting Acute Leukemia of Ambiguous Lineage|Childhood B Acute Lymphoblastic Leukemia|Mixed Phenotype Acute Leukemia National Cancer Institute (NCI) December 2016 --
NCT02877303 Recruiting Leukemia|Acute Lymphoblastic Leukemia M.D. Anderson Cancer Center|Amgen November 2016 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Mercaptopurine (6-MP) | Mercaptopurine (6-MP) supplier | purchase Mercaptopurine (6-MP) | Mercaptopurine (6-MP) cost | Mercaptopurine (6-MP) manufacturer | order Mercaptopurine (6-MP) | Mercaptopurine (6-MP) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID